Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

As MDMA and psilocybin progress through FDA drug development, this systematic review compiles existing research on psychiatric drug-drug interactions with these substances. It identifies which medications may alter the effects or safety of MDMA- and psilocybin-assisted therapy, providing a resource for clinicians and researchers. The review suggests that certain psychiatric drugs, such as SSRIs and other serotonergic agents, can diminish or alter the subjective and physiological responses to MDMA and psilocybin, while others may increase risks. The authors indicate that careful medication management is necessary during psychedelic-assisted therapy to optimize outcomes and minimize adverse events.

Study at a glance

Abstract

As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research on psychiatric drug-drug interactions with MDMA or psilocybin.